1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6A52F78CD8473BC0185257BD50052DF04
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/medical-affairs-in-India-budget-and-staffing-trends-in-emerging-markets?opendocument
18
19opendocument
203.80.4.76
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Medical Affairs » Structure, Staffing and Budgets

Building Best-in-Class Medical Affairs Capabilities In India – Budget and Staffing Trends in Emerging Markets

ID: 5266


Features:

19 Info Graphics

14 Data Graphics

190+ Metrics

6 Narratives


Pages/Slides: 41


Published: Pre-2014


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Building Best-in-Class Medical Affairs Capabilities In India – Budget and Staffing Trends in Emerging Markets"


STUDY OVERVIEW

Pharmaceutical Medical Affairs organizations bridge the gap between commercial and R&D operations and hence are critical for biopharma and medical device organization future growth. In fact, the call for increased transparency in the recent years has increased the responsibility of Medical Affairs at many companies. However, Medical Affairs at many companies in emerging countries, especially India, is still in its infancy. Moreover, Medical Affairs groups in India lack clear value proposition to evolve beyond their traditional role.

Best Practices, LLC's recent case study illustrates how mature and Indian biopharmaceutical companies are allocating their Medical Affairs budget. The study also reviews where FTEs are allocated across the different functions within Medical Affairs, which roles have increased in importance and Medical Affairs budget trends.

KEY TOPICS

  • Medical Affairs: Spend Allocation     
  • Medical Affairs: Staffing 
  • Medical Affairs: Functional Responsibility     
  • Medical Affairs: Budget Trends & Success Factors 
  • Participant Demographic Data 

SAMPLE KEY METRICS
  • Percent of Medical Affairs spend allocated to key MA functions
  • Percent of Medical Affairs FTEs staffed to key functional areas
  • Percent of Medical Affairs spend allocated for outsourcing
  • Which key Medical Affairs functions have become more important
  • What changes in budget and FTE resource levels have you experienced 2011 to 2012 and 2012 to 2013

SAMPLE KEY FINDINGS
  • Spending Highest in Medical Clinical Operations: In India a major part of the Medical Affairs budget (43%) goes to Medical and Clinical research operations, while 25% of  MA spend in mature markets goes to  Medical & Clinical research operations. Smaller portions are allocated to Medical Science Liaisons, Medical Education and Outcomes Research. With Medical Affairs in its early stages in India MSL, MedEd and Outcomes groups are non-existent or in their infancy.

STUDY METHODOLOGY


This study engaged executives from 50 leading healthcare companies. Segmentation analysis was key to examining trends and effective practices. Within the Mature Markets Segment, 41 participants make up the Pharmaceutical Segment, while the Medical Device Segment consists of 12 participants. The India Segment consists of 8 companies working actively in the India market.

Industries Profiled:
Pharmaceutical; Biotech; Health Care; Biopharmaceutical; Diagnostic; Laboratories; Chemical; Technology; Medical Device; Manufacturing; Financial Services; Consumer Products


Companies Profiled:
Pfizer; LifeCell; Biocon; Biogen Idec; Alkem; AstraZeneca; Ipsen; Esteve; Guerbet; Endo Pharmaceuticals; Allergan; BD; Methapharm; GlaxoSmithKline ; Gilead Sciences; Ethicon; Johnson & Johnson; Mylan; Forest Laboratories; MedImmune; Upsher-Smith; Grunenthal; Phillips; Sandoz; Baxter International; ONYX; Xanodyne Pharmaceuticals; ViroPharma; Ranbaxy; Bristol-Myers Squibb; Novartis; Medtronic; Astellas; GE Healthcare; Eisai; Roche; Teva Pharmaceutical Industries Ltd; MSD; Bayer; Boehringer Ingelheim; Shire; Novo Nordisk; Sanofi Pasteur; Genentech; Cubist Pharmaceuticals; UCB Pharma; Sunovion; Valeant

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.